• PDF / 169,552 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 79 Downloads / 177 Views

DOWNLOAD

REPORT

---

1 S

Haematological toxicities and hepatic function impairment: 4 case reports In an open trial, retroactive analysis of 24 patients conducted between June 2006 to June 2008, four patients [ages and sexes not stated] were described; they developed anaemia, neutrophil granulocyte reduction, hepatic function impairment, elevated total bilirubin or platelet reduction, during treatment with irinotecan and nedaplatin for advanced oesophageal squamous cell carcinoma. The patients were enrolled in the study and were diagnosed with advanced oesophageal squamous cell carcinoma and started receiving second-line chemotherapy with IV irinotecan [CPT-11] 65 mg/m2 infusion for 1 hour on day 1 and day 8 and IV nedaplatin 80 mg/m2 infusion on day 1 for 2 hours, over a 3-week cycle. However, they developed grade 4 neutrophil granulocyte reduction (1 patient), grade 3 anaemia (1 patient), grade 2 hepatic function impairment with elevated total bilirubin value twice than normal maximum value (1 patient) and grade 3 platelet reduction (1 patient) [time to reactions onset and outcomes not stated]. Ying-Liu, et al. Combined chemotherapy with irinotecan and nedaplatin as a second-line regimen for patients with advanced esophageal squamous cell carcinoma: A report of 24 cases. [Chinese]. World Chinese Journal of Digestology 18: 298-302, No. 3, 28 Jan 2010. Available from: URL: http://doi.org/10.11569/wcjd.v18.i3.298 [Chinese; 803514509 summarised from a translation]

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830